Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Acurx Pharmaceuticals LLC

Healthcare US ACXP

1.67USD
-0.1(5.65%)

Last update at 2026-06-05T17:24:00Z

Day Range

1.671.77
LowHigh

52 Week Range

1.3321.00
LowHigh

Fundamentals

  • Previous Close 1.77
  • Market Cap6.74M
  • Volume58234
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-5.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.96654M -14.10310M -14.57777M -12.09278M -12.74770M
Minority interest - - - - -
Net income -7.96654M -14.10310M -14.57777M -12.09155M -12.68119M
Selling general administrative 6257.48M 8.70M 8.53M 7.34M 10.78M
Selling and marketing expenses - 8690.57M 8525.64M - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -14.10310M -29.15600M -12.09400M -12.94721M
Ebitda -8.09198M -14.10310M -14.57777M -12.09278M -12.88070M
Depreciation and amortization - 14.10M 14.58M 0.00122M 0.07M
Non operating income net other - - - - -
Operating income -8.09198M -14.10310M -14.57777M -12.09400M -12.88070M
Other operating expenses 8.09M 14.10M 14.58M 12.09M 12.81M
Interest expense - - - 0.00122M 0.07M
Tax provision - - - - -
Interest income 0.13M 0.02M - - -
Net interest income 0.13M 0.02M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -14088.99990M -0.01458M -0.00122M -0.06650M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 8.09M 14.10M 14.58M 12.09M 12.81M
Cost of revenue - - - - -
Total other income expense net 0.13M 0.00000M 0.00000M 0.00122M 0.13M
Discontinued operations - - - - -
Net income from continuing ops -7.96654M -14.10310M -12.72369M -12.09278M -12.74770M
Net income applicable to common shares - - - -12.09278M -12.74770M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.69M 3.86M 7.71M 9.38M 13.25M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets -7548.45888M 0.10M 0.11M - 0.30M
Total liab 2.42M 3.24M 3.04M 2.06M 0.84M
Total stockholder equity 5.27M 0.62M 4.67M 7.32M 12.41M
Deferred long term liab - - - - -
Other current liab 2.42M 3.24M 3.04M - 0.84M
Common stock 0.00235M 0.02M 0.01M 0.01M 0.01M
Capital stock 0.00235M 0.02M 0.01M 0.01M 0.01M
Retained earnings -75.28849M -67.32196M -53.21885M -38.64108M -26.54831M
Other liab - - - - -
Good will - - - - -
Other assets 133.44M 151.25M 234.94M 0.26M 295.30M
Cash 7556.10M 3.71M 7.47M 9.11M 12.96M
Cash and equivalents - - - - -
Total current liabilities 2.42M 3.24M 3.04M 2.06M 0.84M
Current deferred revenue - - - - -
Net debt -7556.10000M -3.70671M -7.47419M -9.11175M -12.95885M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 80.55M 67.92M 57.87M 84.59M 65.50M
Property plant equipment - - - - -
Total current assets 7.69M 3.86M 7.71M 9.38M 13.25M
Long term investments - - - - -
Net tangible assets - - - 7.32M 12.41M
Short term investments - - - - -
Net receivables 0.05M 0.05M 0.13M - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable - - 0.00000M 2.06M 0.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -38.64108M -26.54831M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 133.44M - - - -
Deferred long term asset charges - - - - -
Non current assets total 133.44M 3854.11M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -
Change to liabilities - - - 1.22M 0.39M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 10637.17M 6.62M 8.16M 3.70M 14.80M
Change to operating activities - - - 0.03M -0.24669M
Net income -7966.53800M -14.10310M -14.57777M -12.09278M -12.74770M
Change in cash 3849.39M -3.76748M -1.63756M -3.84709M 9.78M
Begin period cash flow 3706.71M 7.47M 9.11M 12.96M 3.18M
End period cash flow 7556.10M 3.71M 7.47M 9.11M 12.96M
Total cash from operating activities -6787.78200M -10.38343M -9.80088M -7.54229M -5.01370M
Issuance of capital stock 6.80M 6.41M 3.54M 3.70M 14.80M
Depreciation - - - - -
Other cashflows from investing activities - - -0.00001M - -
Dividends paid - - - - -
Change to inventory - - -980.75300M - -
Change to account receivables 0.00271M 0.08M -0.12916M - -
Sale purchase of stock 3808.44M 0.00000M - - -
Other cashflows from financing activities 10626.53M 0.21M 2.22M 0.00001M 14.80M
Change to netincome - - - 3.30M 7.59M
Capital expenditures 0.00000M 0.00000M 0.00001M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.39096M 0.28M 1.01M 1.25M 0.14M
Stock based compensation 1247.40M 3.44M 3.77M 3.30M 6.74M
Other non cash items -68.25404M -0.00009M 0.00023M - 0.85M
Free cash flow -6787.78200M -10.38343M -9.80088M -7.54229M -5.01370M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ACXP
Acurx Pharmaceuticals LLC		 -0.1 5.65% 1.67 - - - 1.28 -3.5397
NVO
Novo Nordisk A/S		 -0.475 1.09% 43.27 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 10.61 2.40% 452.35 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 8.07 1.28% 636.80 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals LLC

259 Liberty Avenue, Staten Island, NY, United States, 10305

Key Executives

Name Title Year Born
Mr. Robert J. DeLuccia Co-Founder & Exec. Chairman 1946
Mr. David P. Luci CPA, CPA, Esq., J.D. Corp. Sec., Co-Founder, Pres, CEO & Director 1967
Mr. Robert G. Shawah CPA, CPA Co-Founder & CFO 1967
Mr. Robert J. DeLuccia Co-Founder & Executive Chairman 1946
Mr. David P. Luci CPA, Esq., J.D. Co-Founder, President, CEO & Director 1967
Mr. David P. Luci CPA, Esq., J.D. Co-Founder, President, CEO, Corporate Secretary & Director 1967
Mr. Robert G. Shawah CPA Co-Founder & CFO 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.